Abstract
Sodium/glucose co-transporter-2 inhibitors (SGLT2i) are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2i prescription is associated with COVID-19, when compared with an active comparator.
We performed a propensity score-matched cohort study with active comparators and a negative control outcome in a large UK-based primary care dataset. Participants prescribed SGLT2i (n=9,948) and a comparator group prescribed dipeptyl-peptidase 4 inhibitors (DPP4i; n=14,917) were followed up from 30th January to 27th July 2020. The primary outcome was confirmed or clinically suspected COVID-19. The incidence rate of COVID-19 was 19.7/1000 person-years among users of SGLT2i and 24.7/1000 person-years among propensity score matched users of DPP4i. The adjusted hazard ratio was 0.92 (95% CI 0.66 to 1.29) and there was no evidence of residual confounding in the negative control analysis. We did not observe an increased risk of COVID-19 in primary care amongst those prescribed SGLT2i compared to DPP4i, suggesting that clinicians may safely use these agents in the everyday care of people with type 2 diabetes during the COVID-19 pandemic.
We performed a propensity score-matched cohort study with active comparators and a negative control outcome in a large UK-based primary care dataset. Participants prescribed SGLT2i (n=9,948) and a comparator group prescribed dipeptyl-peptidase 4 inhibitors (DPP4i; n=14,917) were followed up from 30th January to 27th July 2020. The primary outcome was confirmed or clinically suspected COVID-19. The incidence rate of COVID-19 was 19.7/1000 person-years among users of SGLT2i and 24.7/1000 person-years among propensity score matched users of DPP4i. The adjusted hazard ratio was 0.92 (95% CI 0.66 to 1.29) and there was no evidence of residual confounding in the negative control analysis. We did not observe an increased risk of COVID-19 in primary care amongst those prescribed SGLT2i compared to DPP4i, suggesting that clinicians may safely use these agents in the everyday care of people with type 2 diabetes during the COVID-19 pandemic.
Original language | English |
---|---|
Pages (from-to) | 263-269 |
Journal | Diabetes, obesity & metabolism |
Volume | 23 |
Issue number | 1 |
Early online date | 29 Sept 2020 |
DOIs | |
Publication status | E-pub ahead of print - 29 Sept 2020 |
Keywords
- DPP‐4 inhibitor
- SGLT2 inhibitor
- antidiabetic drug
- pharmaco‐epidemiology
- type 2 diabetes